ArticleJournal for immunotherapy of cancer2025
Response to: Correspondence on "Early dynamics of clinical and laboratory parameters predict primary refractory disease in patients with metastatic urothelial carcinoma receiving atezolizumab" by Gao
Christopher Graser et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.